CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 437 enrolled
Drug / intervention
Vortioxetine (Lu AA21004) +1 moredrug
Likely dose
Vortioxetine (Lu AA21004) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01571453
NCT01571453Phase 3Completed
CompareCT.gov

Randomised, Double-blind, Parallel-group, Active-comparator (Venlafaxine Extended Release), Fixed-dose Study of [Vortioxetine] Lu AA21004 in Major Depressive Disorder in Asian Countries

H. Lundbeck A/S·interventional·Posted Apr 5, 2012·Updated Oct 13, 2014

In Brief

A Phase 3 clinical trial evaluating Vortioxetine (Lu AA21004) and Venlafaxine extended release for Major Depressive Disorder. Completed, enrolled 437 participants.

Detailed Summary

This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 5, 2012
Enrollment StartMay 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.2 years ago

Interventions

Vortioxetine (Lu AA21004)drug

10 mg/day

Venlafaxine extended releasedrug

150 mg/day